Tomita K, Marumo F
Second Department of Internal Medicine, Tokyo Medical and Dental University, Japan.
J Cardiovasc Pharmacol. 1992;19 Suppl 1:S97-101. doi: 10.1097/00005344-199219001-00019.
We assessed the long-term effects of carvedilol on renal function in 10 patients with mild-to-moderate essential hypertension. After a 2- to 4-week placebo run-in period, all patients received 5 mg carvedilol once daily. If the effect was insufficient, the dosage was successively increased to 10 or 20 mg once daily. The mean +/- SEM duration of treatment was 17.3 +/- 1.0 weeks, and the final mean daily dosage was 13.5 +/- 2.2 mg/day. With treatment, systolic and diastolic blood pressures decreased significantly from 159.7 +/- 1.3 to 140.5 +/- 3.2 mm Hg (p less than 0.001) and from 98.3 +/- 1.0 to 88.2 +/- 2.7 mm Hg (p less than 0.001), respectively. Carvedilol did not cause significant changes in glomerular filtration rate, effective renal plasma flow, blood urea nitrogen, or serum creatinine. Renal vascular resistance decreased significantly from 12.7 +/- 1.4 to 11.2 +/- 1.2 dyne.s.cm-5/1.48 m2 x 10(3) (p less than 0.05). Thus, long-term carvedilol therapy was effective in reducing blood pressure in essential hypertension without causing impairment of renal function.
我们评估了卡维地洛对10例轻至中度原发性高血压患者肾功能的长期影响。在进行2至4周的安慰剂导入期后,所有患者每日服用一次5毫克卡维地洛。若效果不佳,剂量依次增至每日10毫克或20毫克。治疗的平均±标准误持续时间为17.3±1.0周,最终平均每日剂量为13.5±2.2毫克/天。治疗后,收缩压和舒张压分别从159.7±1.3显著降至140.5±3.2毫米汞柱(p<0.001)和从98.3±1.0显著降至88.2±2.7毫米汞柱(p<0.001)。卡维地洛未引起肾小球滤过率、有效肾血浆流量、血尿素氮或血清肌酐的显著变化。肾血管阻力从12.7±1.4显著降至11.2±1.2达因·秒·厘米⁻⁵/1.48平方米×10³(p<0.05)。因此,长期卡维地洛治疗可有效降低原发性高血压患者的血压,且不会导致肾功能损害。